文献速递间质性肺疾病

成人肺泡蛋白沉积症:病理生理与临床处理

Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach.
PubMed 文献 · Lancet Respir Med · 2018-02-01

肺泡蛋白沉积症(PAP)是因表面活性物质稳态异常导致脂蛋白样物质在肺泡及肺泡巨噬细胞中蓄积的弥漫性肺病。约90%成人PAP由抗GM-CSF自身免疫导致GM-CSF生物利用度受损所致,其余与巨噬细胞功能异常、GM-CSF受体缺陷或表面活性物质相关基因异常有关。中重度患者全肺灌洗仍是一线治疗,补充GM-CSF也有用但指征与剂量尚不明确。

要点

  • 约90%成人PAP由抗GM-CSF自身免疫导致GM-CSF生物利用度受损引起。
  • 中重度PAP一线治疗为全肺灌洗,补充GM-CSF也有用但细节未明。
  • 利妥昔单抗、血浆置换和肺移植仅用于难治性病例。

核心结论

  • PAP由表面活性物质稳态异常致脂蛋白样物质在肺泡及肺泡巨噬细胞蓄积,约90%成人病例与抗GM-CSF自身免疫相关。

研究设计与样本

  • 综述,总结成人PAP的病理生理与临床处理,未报告检索范围与样本量。

主要发现

  • 约90%成人PAP由抗GM-CSF自身免疫导致GM-CSF生物利用度受损引起。
  • 其余病因包括内源或外源触发因素致巨噬细胞功能异常、GM-CSF受体缺陷及表面活性物质产生的其他遗传异常。
  • PAP通常导致气体交换受损,可引起呼吸困难、低氧血症甚至呼吸衰竭和死亡。
  • PAP患者偶尔发生肺纤维化。

关键数值与推荐

  • 中重度PAP一线治疗为全肺灌洗。
  • 补充GM-CSF也有用,但指征、药物选择和剂量尚不明确。
  • 利妥昔单抗、血浆置换和肺移植仅用于难治性病例。

临床怎么用

  • 成人PAP应首先考虑抗GM-CSF自身免疫病因。
  • 中重度患者首选全肺灌洗,补充GM-CSF可作为治疗选择但需个体化。
  • 难治性病例可考虑利妥昔单抗、血浆置换或肺移植。

局限性

  • 综述未报告检索范围与证据等级。
  • 补充GM-CSF的指征、药物选择和剂量尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary alveolar proteinosis (PAP) is a diffuse lung disease that results from the accumulation of lipoproteinaceous material in the alveoli and alveolar macrophages due to abnormal surfactant homoeostasis. Identification of the granulocyte-macrophage colony-stimulating factor (GM-CSF) as an indispensable mediator of macrophage maturation and surfactant catabolism was the key discovery leading to the current understanding of the pathogenesis of most forms of PAP. Impaired GM-CSF bioavailability due to anti-GM-CSF autoimmunity is the cause of approximately 90% of adult PAP cases. Abnormal macrophage function due to endogenous or exogenous triggers, GM-CSF receptor defects, and other genetic abnormalities of surfactant production account for the remainder of causes. The usual physiological consequence of PAP is impairment of gas exchange, which can lead to dyspnoea, hypoxaemia, or even respiratory failure and death. Pulmonary fibrosis occurs occasionally in patients with PAP. For patients with moderate to severe disease, whole lung lavage is still the first-line treatment of choice. Supplemental GM-CSF is also useful, but details about indications, choice of agent, and dosing remain unclear. Other therapies, including rituximab, plasmapheresis, and lung transplantation have been described but should be reserved for refractory cases.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Kumar A, Abdelmalak B, Inoue Y, et al. Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. Lancet Respir Med. 2018. PMID: 29397349. doi:10.1016/S2213-2600(18)30043-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。